These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30156950)

  • 21. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PANLAR consensus statement on biosimilars.
    Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
    Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
    Buske C; Ogura M; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
    Mellstedt H
    Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of biosimilars in oncology.
    Schellekens H; Smolen JS; Dicato M; Rifkin RM
    Lancet Oncol; 2016 Nov; 17(11):e502-e509. PubMed ID: 27819248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilars for the next decade in Latin America: a window of opportunity.
    Bas TG
    Expert Opin Biol Ther; 2023; 23(8):659-669. PubMed ID: 37542714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rise of oncology biosimilars: from process to promise.
    Verrill M; Declerck P; Loibl S; Lee J; Cortes J
    Future Oncol; 2019 Oct; 15(28):3255-3265. PubMed ID: 31441323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical considerations for the development of biosimilars in oncology.
    Socinski MA; Curigliano G; Jacobs I; Gumbiner B; MacDonald J; Thomas D
    MAbs; 2015; 7(2):286-93. PubMed ID: 25621390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory and clinical considerations for biosimilar oncology drugs.
    Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
    Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
    Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
    J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
    Jacobs I; Ewesuedo R; Lula S; Zacharchuk C
    BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars: Considerations for Oncology Nurses
.
    Vizgirda V; Jacobs I
    Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
    Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
    Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
    de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
    J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.